• 颜婷婷

    药理系教授,中国药科大学兴药领军学者人才计划
    领域:代谢调控与肝病药理
    联系电话:15850696448
    电子邮箱:tingting.yan@cpu.edu.cn
    办公室:江宁校区新实验大楼1期445室
    实验室:江宁校区新实验大楼1期226室
  • 1、教育经历
    (1) 2011/09-2016/06,药学院/药物科学研究院,博士
    (2) 2007/09-2011/07, 中国药科大学,药学院,学士
    2、工作经历
    (1) 2024/01至今,中国药科大学,药学院,教授
    (2) 2016/10-2023/09,美国国立卫生研究院,美国国立癌症研究所,博士后
    3、学术荣誉
    2024, 中国药科大学兴药领军学者人才
    2023, 美国23rd Annual CCR Fellows and Young Investigators Colloquium: Outstanding Oral Presentation
    2022, 美国NIH: Fellows Award for Research Excellence
    2016, 美国NIH: Outstanding Graduate Research
    (1) 基于代谢调控的肝病药物靶标发现和确证
    (2) 代谢导向的中药及天然药物治疗肝病的作用和机理
    1.学术获奖
    NIH: Fellows Award for Research Excellence (FARE) competition, 2022, 排名1/1
    NCI/CCR: Travel Award- Outstanding Oral Presentation, 2023,排名1/1
    Acta Pharmaceutica Sinica B: 2021 High Impact Paper Award, 2021, 排名1/1
    NIH: Outstanding GPP Graduation Research Award, 2016, 排名1/1
    2.代表性科研成果
    (1) 揭示代谢性核受体PPARα在肝肠组织中对脂肪肝病的差异调控作用和机理,并阐明代谢性转录因子CEBPα在肝细胞中通过抑制OPN转录和释放来缓解肝纤维化;
    (2)从代谢角度出发,揭示了天然产物醉茄素A及甘草酸等改善肝病的新作用和机理。
    (1) Yan T, Yan N, Xia Y, Sawaswong V, Zhu X, Dias HB, Aibara D, Takahashi S, Hamada K, Saito Y, Li G, Liu H, Yan H, Velenosi TJ, Krausz KW, Huang J, Kimura S, Rotman Y, Qu A*, Hao H*, Gonzalez FJ*. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression. J Clin Invest, 2024, 134(7):e166731 (IF=15.9)
    (2) Yan T#, Luo Y#, Yan N, Hamada K, Zhao N, Xia Y, Wang P, Zhao C, Qi D, Yang S, Sun L, Cai J, Wang Q, Jiang C, Gavrilova O, Krausz KW, Patel DP, Yu X, Wu X, Hao H, Liu W*, Qu A*, Gonzalez FJ*. Intestinal peroxisome proliferator-activated receptor α-fatty acid-binding protein 1 axis modulates nonalcoholic steatohepatitis. Hepatology, 2023, 77(1):239-255 (IF=13.5)
    (3) Zhang Y#, Yan T#*, Wang T, Liu X, Hamada K, Sun D, Sun Y, Yang Y, Wang J, Takahashi S, Wang Q, Krausz KW, Jiang C, Xie C, Yang X*, Gonzalez FJ*. Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity. Acta Pharm Sin B, 2022, 12(5):2224-2238 (IF=14.5)
    (4) Hamada K#, Wang P#, Xia Y#, Yan N, Takahashi S, Krausz KW, Hao H, Yan T*, Gonzalez FJ*. Withaferin A alleviates ethanol-induced liver injury by inhibiting hepatic lipogenesis. Food Chem Toxicol, 2022, 160:112807 (IF=4.3)
    (5) Yan T#, Luo Y#, Xia Y, Hamada K, Wang Q, Yan N, Krausz KW, Ward JM, Hao H, Wang P*, Gonzalez FJ*. St. John's Wort alleviates dextran sodium sulfate-induced colitis through pregnane X receptor-dependent NFκB antagonism. FASEB J, 2021, 35(11):e21968 (IF=5.8)
    (6) Yagai T#, Yan T#, Luo Y#, Takahashi S, Aibara D, Kim D, Brocker CN, Levi M, Motohashi H, Gonzalez FJ*. Feedback repression of PPARα signaling by Let-7 microRNA. Cell Rep, 2021, 36(6):109506 (IF=10.0)
    (7) Yan T#, Yan N#, Wang H, Yagai T, Luo Y, Takahashi S, Zhao M, Krausz KW, Wang G*, Hao H*, Gonzalez FJ*. FXR-Deoxycholic Acid-TNF-α Axis Modulates Acetaminophen-Induced Hepatotoxicity. Toxicol Sci, 2021, 181(2):273-284 (IF=4.1)
    (8) Xia Y#, Wang P#, Yan N, Gonzalez FJ*, Yan T*. Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3. Cell Death Dis, 2021, 12(2):174 (IF=9.7)
    (9) Zhang Y#, Yan T#, Sun D, Xie C, Wang T, Liu X, Wang J, Wang Q, Luo Y, Wang P, Yagai T, Krausz KW, Yang X*, Gonzalez FJ*. Rutaecarpine inhibits KEAP1-NRF2 interaction to activate NRF2 and ameliorate dextran sulfate sodium-induced colitis. Free Radic Biol Med, 2020, 148:33-41 (IF=8.1)
    (10) Yan T*, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ*. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B, 2020, 10(1):3-18 (IF=11.6)
    课题组长
    颜婷婷 教授
    博士研究生
    颜娜娜(2021级)
    代梦格 (2024级)
    硕士研究生
    聂亮亮(2024级)
    杨影 (2024级)
    Baidu
    sogou